via Merck stock tumbled amid a broad pharma turndown Thursday even though the company racked up more than $5 billion in sales for its blockbuster cancer drug, Keytruda. article source

...SGEN stock jumped on the potential the resolution could give Merck (...hours trading on today's stock market, SGEN stock leapt 2.9% higher..., closing at 170.14. Merck stock sank a fraction near 91....wheelhouse would help guard Merck against looming patent losses for ...expire in 2028, leaving Merck open to rival generics. In ...year.SGEN stock has risen markedly this year on the potential of a Merck takeover. ...

...SGEN stock jumped on the potential the resolution could give Merck (...hours trading on today's stock market, SGEN stock leapt 2.9% higher..., closing at 170.14. Merck stock sank a fraction near 91....wheelhouse would help guard Merck against looming patent losses for ...expire in 2028, leaving Merck open to rival generics. In ...year.SGEN stock has risen markedly this year on the potential of a Merck takeover. ...

via Another biotech standing on shaky financial legs has fallen victim to the bears. Merck partner 4D Pharma has reported that a key lender, Oxford Finance, shoved the UK company into administration after calling in a $14 million loan they couldn’t immediately make good on. Trading in their stock was halted with a market cap that had fallen to a mere £30 million. article source

via Another biotech standing on shaky financial legs has fallen victim to the bears. Merck partner 4D Pharma has reported that a key lender, Oxford Finance, shoved the UK company into administration after calling in a $14 million loan they couldn’t immediately make good on. Trading in their stock was halted with a market cap that had fallen to a mere £30 million. article source

...-Akero Therapeutics, Bristol-Myers Squibb, Merck & Co RTR North American... Therapeutics, Bristol-Myers Squibb and Merck & Co, on Wednesday. HIGHLIGHTS... cuts to hold from buy * Merck & Co Inc MRK.N : ... reported by Reuters on Wednesday. Stock entries are in alphabetical order... objective to $22 from $29 * Merck & Co Inc MRK.N : ... price to $100 from $95 * Merck & Co Inc MRK.N : ...

...-Akero Therapeutics, Bristol-Myers Squibb, Merck & Co RTR North American... Therapeutics, Bristol-Myers Squibb and Merck & Co, on Wednesday. HIGHLIGHTS... cuts to hold from buy * Merck & Co Inc MRK.N : ... reported by Reuters on Wednesday. Stock entries are in alphabetical order... objective to $22 from $29 * Merck & Co Inc MRK.N : ... price to $100 from $95 * Merck & Co Inc MRK.N : ...

... formulation. For one, Merck is testing whether Keytruda could ... Index. Robert Davis, Merck 's chief executive officer, said ...areas." He added that Merck "continues to deliver value on ...lack generic competition. While Merck 's blockbuster Keytruda might not ...significant threat to the stock market, Merck is a good defensive play ...shots on goal work, Merck shareholders might be relieved about ...

... formulation. For one, Merck is testing whether Keytruda could ... Index. Robert Davis, Merck 's chief executive officer, said ...areas." He added that Merck "continues to deliver value on ...lack generic competition. While Merck 's blockbuster Keytruda might not ...significant threat to the stock market, Merck is a good defensive play ...shots on goal work, Merck shareholders might be relieved about ...

...familiar with these frequent management stock sales. Over the last ...timing and amount of the stock sales. So, given all that... a potential sale to Merck or some other Big Pharma, ..., but a cash and Merck stock sale, maybe he doesn't ... up with as much Merck stock, or whatever. Anyone got any ..., or a cash and stock deal. Anyone got any thoughts/... being now invested in Merck (for example) which would seem ...

...familiar with these frequent management stock sales. Over the last ...timing and amount of the stock sales. So, given all that... a potential sale to Merck or some other Big Pharma, ..., but a cash and Merck stock sale, maybe he doesn't ... up with as much Merck stock, or whatever. Anyone got any ..., or a cash and stock deal. Anyone got any thoughts/... being now invested in Merck (for example) which would seem ...

... formulation. For one, Merck is testing whether Keytruda could ... Index. Robert Davis, Merck’s chief executive officer, ...” He added that Merck “continues to deliver value ...lack generic competition. While Merck’s blockbuster Keytruda might ...significant threat to the stock market, Merck is a good defensive play ...shots on goal work, Merck shareholders might be relieved about ...

... formulation. For one, Merck is testing whether Keytruda could ... Index. Robert Davis, Merck’s chief executive officer, ...” He added that Merck “continues to deliver value ...lack generic competition. While Merck’s blockbuster Keytruda might ...significant threat to the stock market, Merck is a good defensive play ...shots on goal work, Merck shareholders might be relieved about ...

... formulation. For one, Merck is testing whether Keytruda could ... Index. Robert Davis, Merck’s chief executive officer, said ...areas.” He added that Merck “continues to deliver value on ...lack generic competition. While Merck’s blockbuster Keytruda might not ...significant threat to the stock market, Merck is a good defensive play ...shots on goal work, Merck shareholders might be relieved about ...

... formulation. For one, Merck is testing whether Keytruda could ... Index. Robert Davis, Merck’s chief executive officer, said ...areas.” He added that Merck “continues to deliver value on ...lack generic competition. While Merck’s blockbuster Keytruda might not ...significant threat to the stock market, Merck is a good defensive play ...shots on goal work, Merck shareholders might be relieved about ...

... people said. Seagen’s stock closed at $175.13 on ...conjugate Trodelvy for breast cancer. Merck was among the companies interested ... Wall Street Journal reported that Merck was in advanced talks to ... a deal on or before Merck’s quarterly results scheduled ... pre-market so far, while Merck is trading marginally lower.However, ... deal noting the ability of Merck to diversify and sustain revenue ...

... people said. Seagen’s stock closed at $175.13 on ...conjugate Trodelvy for breast cancer. Merck was among the companies interested ... Wall Street Journal reported that Merck was in advanced talks to ... a deal on or before Merck’s quarterly results scheduled ... pre-market so far, while Merck is trading marginally lower.However, ... deal noting the ability of Merck to diversify and sustain revenue ...

... mRNA-based vaccines and therapeutics. Merck (ticker: MRK) made the ...to deliver mRNA-based medicines. Merck is paying Orna $150 ...investors wait to see whether Merck will consummate its rumored acquisition... Merck shares were down 0.3% in Tuesday morning trading. The stock is... up 18% so far this year. Merck was an...a Tuesday press release from Merck; specific details weren't disclosed...

... mRNA-based vaccines and therapeutics. Merck (ticker: MRK) made the ...to deliver mRNA-based medicines. Merck is paying Orna $150 ...investors wait to see whether Merck will consummate its rumored acquisition... Merck shares were down 0.3% in Tuesday morning trading. The stock is... up 18% so far this year. Merck was an...a Tuesday press release from Merck; specific details weren't disclosed...